Shanghai Henlius Biotech, Inc. 的 CEO 是谁？

Mr. Jun Zhu 是 Shanghai Henlius Biotech, Inc. 的 Chief Executive Officer，自 2021 加入公司。

HENLIUS 股票的价格表现如何？

HENLIUS 的当前价格为 $68.25，在上个交易日上升了 1.26%。

Shanghai Henlius Biotech, Inc. 的主要业务主题或行业是什么？

Shanghai Henlius Biotech, Inc. 属于 Biotechnology 行业，该板块是 Health Care

Shanghai Henlius Biotech, Inc. 的市值是多少？

Shanghai Henlius Biotech, Inc. 的当前市值是 $11.1B

Shanghai Henlius Biotech, Inc.（02696.HK）股价、图表、新闻与AI分析

Q: HENLIUS 股票的价格表现如何？

HENLIUS 的当前价格为 $68.25，在上个交易日 上升 了 1.26%。

主页

股票

02696.HK

HENLIUS (02696.HK)

Shanghai Henlius Biotech, Inc.

HK$68.25

1.26%

$0.84

休市： Jan 16, 16:00:00 HKT

关键数据

前收盘价

$67.4

开盘价

$67.4

当日区间

$66.55 - $69.9

52周范围

$15.2 - $92

交易量

384.1K

平均成交量

1.1M

每股收益（TTM）

1.69

股息收益率

市值

$11.1B

什么是 HENLIUS？

Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.

功能特性

交易策略